Inflammatory bowel disease and amebiasis

Abstract

Amebiasis affects around 500 million people in the world. Clinical manifestations of intestinal amebiasis can overlap with symptoms of the inflammatory bowel disease (IBD). Many studies evaluated the relationship of IBD patients during exacerbation periods and amoebic colitis as it is important to rule out the infection before starting steroids and/or immunosuppressive treatment. This mini-review focused on the best strategy to diagnose the infection in this specific population, using classical stool analysis for ova and parasites, serology, investigations by PCR and colonoscopy according to the degree of clinical suspicion. It also suggested an algorithm for management approach where patients were divided into asymptomatic carriers vs. symptomatic patients under 5 ASA or immunosuppressive therapy having either a vegetative or cystic form of the infection. All these patients were treated accordingly by intraluminal agents, and nitroimidazole was added in the vegetative form. 5-ASA was not a contraindication for treatment, while immunosuppression is forbidden until after eradiation of EH.Amoebic infection should always be ruled out before starting treatment with steroid or immunosuppressive medications, in order to minimize its deleterious outcomes on IBD patients. Abstract OJGH: https://escipub.com/open-journal-of-gastroenterology-and-hepatology/ Sanyour Joyce et al., OJGH, 2019 x:xx OJGH: https://escipub.com/open-journal-of-gastroenterology-and-hepatology/ 2

Comorbidities involving parasitic diseases: A look at the benefits and complications

“…This relationship is supported by studies that found that immunosuppression caused by diabetes was observed in more than 50% of patients with amoebiasis, reinforcing the need for the diagnosis of T2DM in endemic areas to guide therapeutic management in those infected. 55,56…”

“…This relationship is supported by studies that found that immunosuppression caused by diabetes was observed in more than 50% of patients with amoebiasis, reinforcing the need for the diagnosis of T2DM in endemic areas to guide therapeutic management in those infected. 55,56 Evidence of the mechanism of action of T. cruzi infection under obesogenic and DM conditions has already been documented. A cross-sectional observational study evaluated 361 individuals with an overall mean age of 60.7 years who presented with chronic CD and had migrated from rural to urban centers.…”